Tolerability of sorafenib in the treatment of hepatocellular carcinoma (HCC) in patients with Child A and B liver cirrhosis

被引：0
|
作者：
Schuette, K.
Zimmermann, L.
Bornschein, J.
Huster, D.
Csepregi, A.
Malfertheiner, P.
机构：
[1] Univ Magdeburg, D-39106 Magdeburg, Germany
[2] Hufeland Klinikum, Bad Langensalza, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15593
引用
收藏
页数：2
相关论文
共 50 条
  • [31] BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Bouattour, M.
    Goutte, N.
    Vullierme, M. -P.
    Castelnau, C.
    Farges, O.
    Faivre, S.
    Durand, F.
    Castera, L.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S407 - S407
  • [32] EXPERIENCE IN THE USE O SORAFENIB FOR TREATMENT OF HEPATOCELLULAR CARCINOMA IN (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE IN 3 BRAZILIANS CENTERS
    Alves, Rogerio
    Alves, Daniele E.
    Harriz, Michelle C.
    Viana, Monica V.
    Kondo, Mario
    Terrabuio, Deborah
    Brandalise, Renata
    Chagas, Aline
    Linhares, Livia M.
    Costa, Daniel P.
    Matos, Carla A.
    Baia, Carlos
    Gampell, Otavio
    Poletti, Paula B.
    HEPATOLOGY, 2011, 54 : 1421A - 1422A
  • [33] SAFETY OF SORAFENIB TREATMENT FOR INTERMEDIATE/ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHILD'S A, B OR C: INITIAL RESULTS IN TWO EXPERIENCED CENTERS IN BRAZIL
    Alves, Rogerio C.
    Alves, Daniele
    Mattos, Carla
    Soares, Silvia
    Harriz, Michelle
    Vanini, Henio
    Kondo, Mario
    Guz, Betty
    Gampel, Otavio
    Poletti, Paula
    HEPATOLOGY, 2009, 50 (04) : 1101A - 1102A
  • [34] Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis
    Buccione, D.
    Fatti, G.
    Gallotta, A.
    Loggi, E.
    Di Donato, R.
    Testa, L.
    Saitta, C.
    Santi, V.
    Di Micoli, A.
    Fazio, V.
    Picciotto, A.
    Biasiolo, A.
    Pontisso, P.
    Raimondo, G.
    Trevisani, F.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S95 - S95
  • [35] Efficacy and tolerability of sorafenib in elderly patients with advanced hepatocellular carcinoma
    Wong, H.
    Yau, C. C.
    Yao, T.
    Tang, V.
    Chan, P.
    Chiu, J.
    Fan, S.
    Peon, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE
    Mathurin, P.
    Castells, L.
    Bodoky, G.
    Stal, P.
    Bronowicki, J. -P.
    Gerolami, R.
    Daniele, B.
    Vazquez, J. T.
    Serejo, F.
    Croitoru, A.
    Hubert, A.
    Gorbunova, V.
    Ratziu, V.
    Papandreou, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S399 - S400
  • [37] Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child- Pugh B (7/8) hepatocellular carcinoma (HCC)
    Bhutiani, Neal
    Philips, Prejesh
    Scoggins, Charles R.
    McMasters, Kelly M.
    Potts, Melissa H.
    Martin, Robert C. G.
    HPB, 2016, 18 (07) : 593 - 599
  • [38] Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
    Sadahisa Ogasawara
    Tetsuhiro Chiba
    Yoshihiko Ooka
    Naoya Kanogawa
    Tomoko Saito
    Tenyu Motoyama
    Eiichiro Suzuki
    Akinobu Tawada
    Fumihiko Kanai
    Osamu Yokosuka
    Investigational New Drugs, 2015, 33 : 729 - 739
  • [39] Small solitary hepatocellular carcinoma (HCC) in child a cirrhosis: Prognostic factors of survival in 142 patients
    Nkontchou, G
    Chevret, S
    Mohand, D
    Piejos, N
    Chaffaud, C
    Beaugrand, M
    Trinchet, JC
    JOURNAL OF HEPATOLOGY, 2001, 34 : 93 - 93
  • [40] Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment
    Huang, Xixia
    Wang, Hong
    Zhang, Wenhong
    Gu, Erli
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (05) : 546 - 552
12345